BioTime, Inc.  

(Public, NYSEMKT:BTX)   Watch this stock  
Find more results for NYSEAMEX:BTX
+0.05 (1.83%)
Apr 17 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.68 - 2.87
52 week 2.59 - 4.82
Open 2.73
Vol / Avg. 107,077.00/242,121.00
Mkt cap 193.48M
P/E     -
Div/yield     -
EPS -0.79
Shares 69.60M
Beta 1.20
Inst. own 27%
May 5, 2014
Q1 2014 BioTime, Inc. Earnings Release (Estimated) Add to calendar
Apr 8, 2014
BioTime, Inc. at Needham Healthcare Conference - Webcast
Mar 26, 2014
BioTime, Inc. at Alliance for Regenerative Medicine RegenMed Investor Day
Mar 17, 2014
Q4 2013 BioTime Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1376.76% -1193.17%
Operating margin -1547.88% -1262.54%
EBITD margin - -1173.40%
Return on average assets -235.95% -120.97%
Return on average equity -567.14% -359.91%
Employees 106 -
CDP Score - -


United States - Map
+1-510-5213390 (Phone)
+1-510-5213389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


BioTime, Inc. is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. Its focus is to provide regenerative therapies for age-related degenerative diseases. In January 2011, the Company acquired the assets of Cell Targeting, Inc. (CTI), a biotechnology company focused on methods of painting molecules on the surface of cells, which in turn causes the cells to adhere to particular tissues, such as those afflicted with disease. In October 2013, Geron Corporation announced the closing of the transaction to divest the Company's stem cell assets to Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc.

Officers and directors

Alfred D. Kingsley Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Michael D. West Ph.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Robert W. Peabody CPA Chief Financial Officer, Chief Operating Officer, Senior Vice President
Age: 58
Bio & Compensation  - Reuters
Lesley Stolz Ph.D. Executive Vice President - Corporate Development
Bio & Compensation  - Reuters
Judith Segall Vice President - Administration, Corporate Secretary, Director
Age: 60
Bio & Compensation  - Reuters
William P. Tew Ph.D. Chief Commercial Officer
Age: 67
Bio & Compensation  - Reuters
Deborah J. Andrews Director
Age: 56
Bio & Compensation  - Reuters
David Schlachet Director
Age: 68
Bio & Compensation  - Reuters
Neal C. Bradsher Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen C. Farrell CPA Independent Director
Age: 47
Bio & Compensation  - Reuters